Preclinical Gene Therapy CV Deals: $98M Median Upfront in 2026

The median upfront payment for a preclinical gene therapy deal in cardiovascular is $98M, based on 10 comparable transactions closed between 2024 and 2025. The interquartile range spans $62M to $224M, and the median total deal value sits at $2.01B. If you are a biotech founder pricing a preclinical cardiovascular asset or a BD team benchmarking an inbound opportunity, these are your reference points — not hypotheticals, not analyst projections, but closed-deal economics.

That said, the spread is enormous. A 3.6x gap between P25 and P75 means the specifics of your asset, your competitive position, and your negotiating leverage matter far more than any single benchmark number. This article breaks down what drives that range and how to position accordingly.

The Numbers — Preclinical Cardiovascular Deal Benchmarks

Below are the core benchmarks for preclinical gene therapy deals in cardiovascular, derived from 10 transactions. Use these as your starting grid when modeling term sheets or evaluating inbound offers.

Two things jump out immediately. First, the median upfront of $98M is high for preclinical — significantly above the all-modality preclinical median, which typically lands in the $20M–$40M range. Gene therapy commands a premium because the development risk profile is different: manufacturing is capital-intensive, clinical programs are smaller, and the regulatory path through breakthrough or accelerated designations can compress timelines. Second, a $2.01B median TDV signals that buyers are structuring these deals with substantial milestone-heavy back ends, which means licensors should scrutinize milestone achievability as aggressively as the upfront number. For deeper Cardiovascular Benchmarks, the platform tracks the full milestone waterfall.

What Recent Deals Show

The Verve–Lilly deal is the outlier that reshapes every conversation in this space. A $598M upfront for a cardiovascular gene therapy program is not normal. It reflects Lilly's strategic urgency to build a genetic medicines franchise, Verve's differentiated in vivo base editing approach targeting PCSK9, and the fact that Verve had already generated human proof-of-concept data from its VERVE-101 program — stretching the definition of "preclinical" in terms of platform validation. Strip out Verve, and the median drops closer to $95M–$100M, which is exactly where Sirius–CRISPR and CSPC–AstraZeneca landed.

At the other extreme, Tenaya's $10M upfront with Alnylam reflects an early-stage collaboration structured more as an option than a full license. The $1.14B TDV suggests the parties agreed the science was promising but far from de-risked — so the economics were almost entirely back-loaded. This is a classic structure when the licensor has interesting biology but limited preclinical proof-of-concept data.

The Shanghai Argo–Novartis deal at $185M upfront with a $4.2B TDV represents the China-origin asset premium that has emerged in cardiovascular gene therapy. Novartis paid for global rights to a differentiated construct, and the headline TDV reflects the blockbuster commercial potential Novartis models for a genetically validated cardiovascular target.

What Drives the Range

A $62M-to-$224M interquartile range does not happen randomly. Four variables explain most of the variance in how much upfront you can extract for a preclinical cardiovascular gene therapy asset:

• Differentiated mechanism and target validation. Genetically validated targets — PCSK9, ANGPTL3, Lp(a) — command premiums because the clinical probability of success is structurally higher. If your gene therapy addresses a target with human genetic proof that loss-of-function is cardioprotective, you are in P75 territory. Novel targets without that genetic anchor land at P25 or below.
• Competitive landscape density. Cardiovascular gene therapy is getting crowded fast. Verve, Silence Therapeutics, and multiple base editing players are competing for the same targets. If three other programs are hitting PCSK9, your leverage erodes unless your delivery system, durability profile, or manufacturing cost structure is demonstrably superior. Buyers discount upfronts when they have optionality.
• Regulatory pathway clarity. Assets with a credible path to breakthrough therapy designation or accelerated approval attract higher upfronts because they compress the timeline to revenue. A program targeting homozygous familial hypercholesterolemia (HoFH) with no approved gene therapy has a cleaner regulatory narrative than one targeting a broader, better-served dyslipidemia population.
• Buyer urgency and strategic fit. Lilly's $598M upfront to Verve was driven by Lilly's publicly stated ambition to build a genetic medicines portfolio. When a buyer needs an asset to fill a declared strategic gap — and the market knows it — pricing power shifts decisively to the licensor. AstraZeneca's $100M to CSPC, while substantial, reflects a more measured approach from a buyer with existing cardiovascular infrastructure.

How to Position Your Deal

If you are a biotech founder preparing to out-license a preclinical cardiovascular gene therapy asset, here is the honest framework for where you will land:

$150M+ upfront (P75 and above): You need at least three of the following — a genetically validated target with clear human LOF data, a differentiated delivery or editing platform, limited direct competition at the same target, and at least two motivated buyers in parallel. The Verve deal proves that platform-level differentiation combined with buyer urgency can push well above P75, but that deal is not your comp unless your data package is comparably de-risked.

$80M–$150M upfront (median range): This is where most quality preclinical gene therapy assets land. You have solid target validation, reasonable preclinical efficacy and safety data in relevant animal models, and a manufacturing path that does not terrify the buyer's CMC team. The Sirius–CRISPR and CSPC–AstraZeneca deals are your true comps. To stay in this range, your data package needs to be clean and your IP position defensible.

Below $62M upfront (P25 and below): You are here if your target validation is thin, your preclinical package is incomplete, or you are competing against multiple programs at the same target with more data. The Tenaya–Alnylam structure at $10M upfront is what happens when the buyer sees optionality value but not enough de-risking to justify a large upfront commitment. If you are in this zone, negotiate hard on milestone structure and royalty rates — the back-end economics become your primary value capture mechanism.

Three tactical levers consistently move upfronts higher in this space:

• Run a competitive process. Bilateral negotiations in cardiovascular gene therapy leave money on the table. At least two of the five sample deals above involved competitive dynamics that lifted the upfront. Engage 3–5 potential partners simultaneously.
• Invest in IND-enabling studies before signing. Every dollar you spend on GLP tox and manufacturing process development between now and term sheet reduces buyer risk and directly inflates the upfront. A shovel-ready IND package shifts the perceived phase from preclinical to "near-clinical" and can add $30M–$60M to the upfront.
• Structure creatively. If the buyer will not move on upfront, push for near-term milestones — IND filing, first patient dosed — that are achievable within 12–18 months. These function as quasi-upfront payments and improve your effective upfront economics without changing the headline number the buyer reports to their board.

Use the Deal Calculator to model where your specific asset falls within this range based on target, data maturity, and competitive dynamics.

Run your own benchmark with the Ambrosia calculator. The platform covers 1,500+ biopharma deals across every modality, therapeutic area, and development stage — filterable by upfront, TDV, royalty structure, and milestone composition. Stop guessing. Start benchmarking against real transaction data.